Home > News > Nanogen Expands Real-Time Portfolio
April 25th, 2006
Nanogen Expands Real-Time Portfolio
Abstract:
Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products announced today it has expanded its molecular reagent product portfolio to include real-time probes and primers designed to detect the presence of Epstein-Barr virus (EBV). EBV is the causative agent of infectious mononucleosis and also underlies several other lymphoproliferative disorders such as Burkitt's lymphoma.
Source:
Nanogen
Related News Press |
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||